Anavex Life Sciences Stock Surges 8.8% as New Clinical Milestones Boost Investor Confidence

Anavex Life Sciences Corp. Corporate Update

• Stock Performance

• On Wednesday, 21 October 2026, Anavex Life Sciences (AVXL) closed 8.8 % higher at 11:07 PM Central Europe.

• The current share price is approximately USD 1.36 on major exchanges.

• Outstanding shares total 92.7 million.

• Market capitalization stands at USD 115.9 million.

• Trading volume over the last 24 hours was about USD 2.3 million.

• From the end of the previous month to the present, the stock has declined 43.33 %.

• The 200‑day simple moving average is USD 3.21.

• The 52‑week high was USD 9.4 on 23 October 2025.

• The 52‑week low was USD 1.14 on 19 October 2026.

• Recent Clinical Milestones (20 October 2026)

• Completion of drug‑drug interaction and absorption‑distribution‑metabolism‑excretion studies for blarcamesine (ANAVEX 2‑73) in healthy volunteers receiving 30 mg.

• No serious adverse events reported; safety and pharmacokinetic data are undergoing full analysis.

• The U.S. Food and Drug Administration has approved the Investigational New Drug application for the Fragile X syndrome indication.

• A November meeting has been scheduled to discuss the inclusion of pediatric participants in the Phase 3 Rett syndrome study.

• These events are positioned as key milestones supporting ongoing clinical development across the company’s three core indications.

• Peer Stock Movements (Last 24 Hours)

• Company Overview Anavex Life Sciences Corp. is a biopharmaceutical firm listed on the Nasdaq. The company focuses on precision genetic medicine for severe neurological disorders, rare diseases, and high‑risk CNS patient populations. Global operations are supported through its website at www.anavex.com .